

# Oral semaglutide key clinical trials

Rybelsus® (oral semaglutide) is the first glucagon-like peptide 1 receptor agonist (GLP-1 RA) in a pill for the treatment of type 2 diabetes. It has been studied in a large Phase 3a clinical trial programme called PIONEER (peptide innovation for early diabetes treatment). **This overview highlights the trials focused on glycaemic control.**



The primary endpoint of PIONEER trials 1-5 and PIONEER 8 is change in HbA<sub>1c</sub> from baseline to week 26.<sup>1-5, 7</sup>



The primary endpoint of PIONEER 7 is the proportion of patients achieving the treatment target of HbA<sub>1c</sub> below 7% at week 52.<sup>6</sup>

## Across the PIONEER programme:



Oral semaglutide demonstrated significantly better HbA<sub>1c</sub> reduction and unsurpassed weight loss vs sitagliptin, empagliflozin and liraglutide<sup>2-4</sup>




Oral semaglutide had a safe and well-tolerated profile consistent with the GLP-1 RA class, with the most common adverse event being nausea<sup>1-7</sup>

All results featured are based on end of trial data/results with treatment policy estimand\*

\* Treatment policy estimand includes data from all randomised subjects regardless of discontinuation of trial product and/or use of rescue medication


## HbA<sub>1c</sub> change from baseline




\*Statistically significant compared with placebo or active comparator.

1. Aroda VR, et al. *Diabetes Care* 2019;42:1724-32; 2. Rodbard HW et al. *Diabetes Care*. 2019;42(12):2272-2281; 3. Rosenstock J et al. *JAMA*. 2019;321(15):1466-1480; 4. Pratley R, et al. *Lancet* 2019;394:39-50; 5. Mosenzon O, et al. *Lancet Diabetes Endocrinol* 2019;7:515-27; 6. Pieber TR, et al. *Lancet Diabetes Endocrinol* 2019;7:528-39; 7. Zinman B et al. *Diabetes Care*. 2019;42(12):2262-2271

# Body weight change from baseline



# Proportion of patients with HbA<sub>1c</sub> <7.0%



1. Aroda VR, et al. *Diabetes Care* 2019;42:1724-32; 2. Rodbard HW et al. *Diabetes Care*. 2019;42(12):2272-2281; 3. Rosenstock J et al. *JAMA*. 2019;321(15):1466-1480; 4. Pratley R, et al. *Lancet* 2019;394:39-50; 5. Mosenzon O, et al. *Lancet Diabetes Endocrinol* 2019;7:515-27; 6. Pieber TR, et al. *Lancet Diabetes Endocrinol* 2019;7:528-39; 7. Zinman B et al. *Diabetes Care*. 2019;42(12):2262-2271